首页 | 本学科首页   官方微博 | 高级检索  
检索        

3种保肝用药方案治疗乙型肝炎肝硬化的最小成本分析
引用本文:费平霞,杨学辉,文友民.3种保肝用药方案治疗乙型肝炎肝硬化的最小成本分析[J].中国药房,2010(38):3558-3560.
作者姓名:费平霞  杨学辉  文友民
作者单位:宁夏医科大学附属医院药剂科,银川市750004
摘    要:目的:评价3种保肝用药方案治疗乙型肝炎肝硬化的经济学效果。方法:将遴选出的95例乙型肝炎肝硬化患者随机分为A、B、C组,在应用注射用门冬氨酸鸟氨酸的基础上,分别联合应用注射用肝水解肽、注射用还原型谷胱甘肽钠、复方二氯醋酸二异丙胺注射液进行保肝治疗,疗程均为7~21d,观察疗效,并进行最小成本分析。结果:A、B、C组的治疗时间分别为(14.42±6.44)、(12.40±5.89)、(15.79±6.19)d;总有效率分别为67.7%、80.0%、76.5%,差异无统计学意义(P>0.05);总成本分别为(4853.58±2128.43)、(3425.37±1585.51)、(4959.67±1909.49)元。结论:B组方案最佳。

关 键 词:乙型肝炎  肝硬化  药物经济学  最小成本分析

Cost-minimization Analysis of 3 Kinds of Therapeutic Regimens for Hepatic Cirrhosis Caused by Hepatitis B
FEI Ping-xia,YANG Xue-hui,WEN You-min.Cost-minimization Analysis of 3 Kinds of Therapeutic Regimens for Hepatic Cirrhosis Caused by Hepatitis B[J].China Pharmacy,2010(38):3558-3560.
Authors:FEI Ping-xia  YANG Xue-hui  WEN You-min
Institution:(Dept.of Pharmacy,The Affiliated Hospital of Ningxia Medical University,Yinchuan 750004,China)
Abstract:OBJECTIVE:To evaluate the economic efficacy of 3 kinds of therapeutic regimens in the treatment of hepatic cirrhosis caused by hepatitis B.METHODS:A total of 95 patients with hepatic cirrhosis caused by hepatitis B were randomized into 3 groups.3 groups received L-ornithine L-aspartate for injection.3 groups were additionally given Heparolysate for injection,Re-duced glutathione sodium for injection or Compound diisopropylamine dichloroacetate injection for 7 to 21 days,respectively.The curative effects were recorded and the cost-minimization analysis was conducted.RESULTS:In group A,group B and group C,the course of treatments were(14.42±6.44)days,(12.40±5.89)days and(15.79±6.19)days,respectively;the total effective rates of group A,group B and group C were 67.7%,80.0% and 76.5%,respectively,showing no statistical significance among 3 groups(P0.05);the total costs were(4 853.58±2 128.43)yuan,(3 425.37±1 585.51)yuan and(4 959.67±1 909.49)yuan,respectively.CONCLUSION:The therapeutic regimen for group B is the best one among 3 kinds of therapeutic regimens in terms of cost-minimization.
Keywords:Hepatitis B  Hepatic cirrhosis  Pharmacoeconomics  Cost-minimization analysis
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号